TY - JOUR
T1 - Automatic assessment of glioma burden
T2 - A deep learning algorithm for fully automated volumetric and bidimensional measurement
AU - Chang, Ken
AU - Beers, Andrew L.
AU - Bai, Harrison X.
AU - Brown, James M.
AU - Ina Ly, K.
AU - Li, Xuejun
AU - Senders, Joeky T.
AU - Kavouridis, Vasileios K.
AU - Boaro, Alessandro
AU - Su, Chang
AU - Bi, Wenya Linda
AU - Rapalino, Otto
AU - Liao, Weihua
AU - Shen, Qin
AU - Zhou, Hao
AU - Xiao, Bo
AU - Wang, Yinyan
AU - Zhang, Paul J.
AU - Pinho, Marco C.
AU - Wen, Patrick Y.
AU - Batchelor, Tracy T.
AU - Boxerman, Jerrold L.
AU - Arnaout, Omar
AU - Rosen, Bruce R.
AU - Gerstner, Elizabeth R.
AU - Yang, Li
AU - Huang, Raymond Y.
AU - Kalpathy-Cramer, Jayashree
N1 - Funding Information:
Research reported in this publication was supported by a training grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health under award number 5T32EB1680 and by the National Cancer Institute (NCI) of the National Institutes of Health under Award Number F30CA239407 to K.C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Other funding included National Institutes of Health grants R01CA129371 to T.T.B.; K23CA169021 to E.R.G.; and U01 CA154601, U24 CA180927, and U24 CA180918 to J.K-C.; the National Natural Science Foundation of China (81301988 to L.Y., 81472594/81770781 to X.L., 81671676 to W.L.), and the Shenghua Yuying Project of Central South University to L.Y. This research was carried out in whole or in part at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Biotechnology Resource Grant supported by NIBIB, National Institutes of Health.
Funding Information:
research support from Agios, Astra Zeneca, Beigene, Eli Lily, Genentech/Roche, Kazia, Merck, MediciNova, Novartis, Oncoceutics, Sanofi-Aventis, Vascular Biogenics, and VBI Vaccines; is on the advisory board for Abbvie, Agios, Astra Zeneca, Agios, Eli Lilly, Genentech/Roche, Immunomic Therapeutics, Kayetek, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines; and is a speaker for Merck and Prime Oncology. T.T.B. has received research support from Champions Biotechnology, AstraZeneca, Pfizer, and Millennium. He is on the advisory board for UpToDate, Inc, and is a consultant for Genomicare, Merck, NXDC, Amgen, Roche, Oxigene, Foundation Medicine, Proximagen. He has provided CME lectures or material for UpToDate, Research to Practice, Oakstone Medical Publishing, and Imedex. B.R.R. is on the advisory board for ARIA, Butterfly, Inc, DGMIF (Daegu-Gyeongbuk Medical Innovation Foundation), QMENTA, and Subtle Medical, Inc; is a consultant for Broadview Ventures, Janssen Scientific, ECRI Institute, GlaxoSmithKline, Hyperfine Research, Inc, Peking University, Wolf Greenfield, Superconducting Systems, Inc, Robins Kaplin, LLC, Millennium Pharmaceuticals, GE Healthcare, Siemens, Quinn Emanuel Trial Lawyers, Samsung, and Shenzhen Maternity & Child Healthcare Hospital; and is a founder of BLINKAI Technologies, Inc. J.K. is a consultant/advisory board member for Infotech, Soft. The other authors declare no competing interests.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/11/4
Y1 - 2019/11/4
N2 - Background: Longitudinal measurement of glioma burden with MRI is the basis for treatment response assessment. In this study, we developed a deep learning algorithm that automatically segments abnormal fluid attenuated inversion recovery (FLAIR) hyperintensity and contrast-enhancing tumor, quantitating tumor volumes as well as the product of maximum bidimensional diameters according to the Response Assessment in Neuro-Oncology (RANO) criteria (AutoRANO). Methods: Two cohorts of patients were used for this study. One consisted of 843 preoperative MRIs from 843 patients with low-or high-grade gliomas from 4 institutions and the second consisted of 713 longitudinal postoperative MRI visits from 54 patients with newly diagnosed glioblastomas (each with 2 pretreatment "baseline" MRIs) from 1 institution. Results: The automatically generated FLAIR hyperintensity volume, contrast-enhancing tumor volume, and AutoRANO were highly repeatable for the double-baseline visits, with an intraclass correlation coefficient (ICC) of 0.986, 0.991, and 0.977, respectively, on the cohort of postoperative GBM patients. Furthermore, there was high agreement between manually and automatically measured tumor volumes, with ICC values of 0.915, 0.924, and 0.965 for preoperative FLAIR hyperintensity, postoperative FLAIR hyperintensity, and postoperative contrast-enhancing tumor volumes, respectively. Lastly, the ICCs for comparing manually and automatically derived longitudinal changes in tumor burden were 0.917, 0.966, and 0.850 for FLAIR hyperintensity volume, contrast-enhancing tumor volume, and RANO measures, respectively. Conclusions: Our automated algorithm demonstrates potential utility for evaluating tumor burden in complex posttreatment settings, although further validation in multicenter clinical trials will be needed prior to widespread implementation.
AB - Background: Longitudinal measurement of glioma burden with MRI is the basis for treatment response assessment. In this study, we developed a deep learning algorithm that automatically segments abnormal fluid attenuated inversion recovery (FLAIR) hyperintensity and contrast-enhancing tumor, quantitating tumor volumes as well as the product of maximum bidimensional diameters according to the Response Assessment in Neuro-Oncology (RANO) criteria (AutoRANO). Methods: Two cohorts of patients were used for this study. One consisted of 843 preoperative MRIs from 843 patients with low-or high-grade gliomas from 4 institutions and the second consisted of 713 longitudinal postoperative MRI visits from 54 patients with newly diagnosed glioblastomas (each with 2 pretreatment "baseline" MRIs) from 1 institution. Results: The automatically generated FLAIR hyperintensity volume, contrast-enhancing tumor volume, and AutoRANO were highly repeatable for the double-baseline visits, with an intraclass correlation coefficient (ICC) of 0.986, 0.991, and 0.977, respectively, on the cohort of postoperative GBM patients. Furthermore, there was high agreement between manually and automatically measured tumor volumes, with ICC values of 0.915, 0.924, and 0.965 for preoperative FLAIR hyperintensity, postoperative FLAIR hyperintensity, and postoperative contrast-enhancing tumor volumes, respectively. Lastly, the ICCs for comparing manually and automatically derived longitudinal changes in tumor burden were 0.917, 0.966, and 0.850 for FLAIR hyperintensity volume, contrast-enhancing tumor volume, and RANO measures, respectively. Conclusions: Our automated algorithm demonstrates potential utility for evaluating tumor burden in complex posttreatment settings, although further validation in multicenter clinical trials will be needed prior to widespread implementation.
KW - RANO
KW - deep learning
KW - glioma
KW - longitudinal response assessment
KW - segmentation
UR - http://www.scopus.com/inward/record.url?scp=85074554240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074554240&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noz106
DO - 10.1093/neuonc/noz106
M3 - Article
C2 - 31190077
AN - SCOPUS:85074554240
SN - 1522-8517
VL - 21
SP - 1412
EP - 1422
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 11
ER -